PegBio Co., Ltd.   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Suzhou China (2008)

Organization Overview

First Clinical Trial
2014
NCT02084251
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

PegBio Co., Ltd.

Active Ingredients

Drugs in Phase 3 Trials (2)

pb-201 (2 trials)

vildagliptin (1 trial)

Drugs in Phase 2 Trials (2)

pb-119 (6 trials)

sitagliptin (januvia) (1 trial)

Drugs in Phase 1 Trials (2)

buspirone (buspar) (1 trial)

exenatide (byetta) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Diabetes Mellitus (Phase 2)

Diabetes Mellitus, Type 2 (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 9
  • # of Trial APIs: 6